Navigation Links
Sanofi Pasteur Presents Additional Data on Investigational Quadrivalent Influenza Vaccine
Date:10/21/2011

oth Victoria and Yamagata lineages have circulated with varying prevalence, making it difficult to predict the next season's dominant lineage. Even in years when there was a good match to one B lineage strain, some influenza disease was caused by the other B lineage omitted from the vaccine. This led to the addition of a second B lineage strain in a quadrivalent formulation which may reduce influenza morbidity and mortality.

"The clinical significance of influenza B, the second most common cause of influenza-related complications and death after H3N2, is often overlooked," said Greenberg. "The results of our investigational studies to date continue to suggest that QIV has the potential to be a useful alternative to currently licensed influenza vaccines by including both B lineages that have been in circulation for the past decade. Thus, Sanofi Pasteur is continuing its clinical development program for this new vaccine which we believe will offer public health benefits." 

Study Design The study objectives included demonstration of non-inferiority of antibody responses to QIV compared with TIV, as assessed by geometric mean titer (GMT) ratios and seroconversion rates for each of the four virus strains among people age 65 years and older. Additional objectives of the study were to demonstrate superiority of antibody responses 21 days post-vaccination to each B strain in QIV compared with the TIV that does not contain the corresponding B strain, as assessed by GMT ratios and seroconversion rates among the study participants.

In the double-blind, active-controlled, multicenter study, 675 healthy people 65 years of age and older were randomized 1:1:1 to receive one intramuscular dose of 2010-2011 licensed TIV (Fluzone vaccine, containing B/Brisbane/60/2008) [Victoria lineage]), investigational TIV (containing B/Florida/04/2006) [Yamagata lineage]) or QIV (containing both B strains). All three vaccines contained the same
'/>"/>

SOURCE Sanofi Pasteur
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4 5

Related medicine technology :

1. Vical Licensee Sanofi-aventis Initiates Phase 3 Trial to Reduce Amputations
2. Sanofi Pasteur Receives FDA Approval of Meningococcal Vaccine for Children
3. Sanofi Pasteur Initiates Phase II Trial of Cell Culture-Based Seasonal Influenza Vaccine
4. Sanofi Pasteur to Donate 60 Million Doses of H5N1 Vaccine to WHO Over 3 Years for its Influenza Vaccine Global Stockpile
5. Sanofi Pasteur Shipping First Doses of Influenza Vaccine for the 2008-2009 Season in the US
6. Insulin Analogues From Novo Nordisk, Eli Lilly and Sanofi-Aventis Will Drive Growth in the Type 1 Diabetes Drug Market
7. Sanofi Aventis: People With Type 2 Diabetes Treated With LANTUS(R) and APIDRA(R) Achieved Greater Reductions in A1C Than Those Treated With Pre-mixed Insulin
8. Sanofi Pasteur Starts a Phase II Study of a Vaccine Against Clostridium Difficile
9. Sanofi Pasteur Dengue Vaccine Enters Pediatric Efficacy Clinical Study
10. Sanofi-aventis Stands Behind the Safety of Lantus(R)
11. Sanofi Pasteur Submits Supplemental Application for A(H1N1) Pandemic Vaccine to U.S. FDA
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/19/2014)... 2014 In today,s rapidly changing, highly ... tools are essential for survival. The world is ... desires, preferences, and unmet needs are evolving rapidly. ... across all industries are continually searching for innovative ... adoption of new market research techniques like mobile ...
(Date:12/19/2014)... Somewhere between dropping five pounds and cooking ... Audicus , a next-generation hearing aids company, will ... Hearing loss is the third most common ... is often unaddressed. Forty-eight million Americans have hearing loss, ... mainly due to price. Hearing aids traditionally cost $7,000 ...
(Date:12/19/2014)... Dec. 18, 2014 Capnia, Inc. (NASDAQ: ... of medical diagnostics based on its proprietary Sensalyze™ ... today announced financial results for the third quarter ... "Following the completion of our initial public ... maximize the recently initiated CoSense® commercial launch," said ...
Breaking Medicine Technology:Study Uncovers New Tools and Techniques for Understanding Consumer Decision Making 2Audicus Will Help People Resolve to Hear Better in 2015 2Capnia Reports Third Quarter 2014 Financial Results 2Capnia Reports Third Quarter 2014 Financial Results 3Capnia Reports Third Quarter 2014 Financial Results 4Capnia Reports Third Quarter 2014 Financial Results 5Capnia Reports Third Quarter 2014 Financial Results 6Capnia Reports Third Quarter 2014 Financial Results 7Capnia Reports Third Quarter 2014 Financial Results 8
... Pharmaceuticals, Inc. (NASDAQ: AUXL ), a ... data from the Collagenase Optimal Reduction of Dupuytren,s ... XIAFLEX ® (collagenase clostridium histolyticum) in the ... palpable cord. This five year observational study was ...
... Company remains committed to speeding innovation to ... boasts 70 potential medicines in clinical development, including 33 in Phases ... potential new medicines in Phase III by the end of 2011, ... as neuroscience, diabetes and oncology, as well as new areas such ...
Cached Medicine Technology:Auxilium Pharmaceuticals Announces Results from Three Year CORDLESS Extension Study in Dupuytren's Contracture 2Auxilium Pharmaceuticals Announces Results from Three Year CORDLESS Extension Study in Dupuytren's Contracture 3Auxilium Pharmaceuticals Announces Results from Three Year CORDLESS Extension Study in Dupuytren's Contracture 4Auxilium Pharmaceuticals Announces Results from Three Year CORDLESS Extension Study in Dupuytren's Contracture 5Auxilium Pharmaceuticals Announces Results from Three Year CORDLESS Extension Study in Dupuytren's Contracture 6Auxilium Pharmaceuticals Announces Results from Three Year CORDLESS Extension Study in Dupuytren's Contracture 7Auxilium Pharmaceuticals Announces Results from Three Year CORDLESS Extension Study in Dupuytren's Contracture 8Auxilium Pharmaceuticals Announces Results from Three Year CORDLESS Extension Study in Dupuytren's Contracture 9Lilly Outlines For Investors How Its Innovation-Based Strategy and Robust Pipeline Will Drive Future Growth Following Upcoming Patent Expirations 2Lilly Outlines For Investors How Its Innovation-Based Strategy and Robust Pipeline Will Drive Future Growth Following Upcoming Patent Expirations 3Lilly Outlines For Investors How Its Innovation-Based Strategy and Robust Pipeline Will Drive Future Growth Following Upcoming Patent Expirations 4Lilly Outlines For Investors How Its Innovation-Based Strategy and Robust Pipeline Will Drive Future Growth Following Upcoming Patent Expirations 5Lilly Outlines For Investors How Its Innovation-Based Strategy and Robust Pipeline Will Drive Future Growth Following Upcoming Patent Expirations 6Lilly Outlines For Investors How Its Innovation-Based Strategy and Robust Pipeline Will Drive Future Growth Following Upcoming Patent Expirations 7Lilly Outlines For Investors How Its Innovation-Based Strategy and Robust Pipeline Will Drive Future Growth Following Upcoming Patent Expirations 8Lilly Outlines For Investors How Its Innovation-Based Strategy and Robust Pipeline Will Drive Future Growth Following Upcoming Patent Expirations 9Lilly Outlines For Investors How Its Innovation-Based Strategy and Robust Pipeline Will Drive Future Growth Following Upcoming Patent Expirations 10Lilly Outlines For Investors How Its Innovation-Based Strategy and Robust Pipeline Will Drive Future Growth Following Upcoming Patent Expirations 11Lilly Outlines For Investors How Its Innovation-Based Strategy and Robust Pipeline Will Drive Future Growth Following Upcoming Patent Expirations 12Lilly Outlines For Investors How Its Innovation-Based Strategy and Robust Pipeline Will Drive Future Growth Following Upcoming Patent Expirations 13Lilly Outlines For Investors How Its Innovation-Based Strategy and Robust Pipeline Will Drive Future Growth Following Upcoming Patent Expirations 14Lilly Outlines For Investors How Its Innovation-Based Strategy and Robust Pipeline Will Drive Future Growth Following Upcoming Patent Expirations 15Lilly Outlines For Investors How Its Innovation-Based Strategy and Robust Pipeline Will Drive Future Growth Following Upcoming Patent Expirations 16
(Date:12/22/2014)... Explorys, the leader in big data-driven healthcare transformation, ... Yarrington as Vice President of Operations, Adam Wallace as ... President of Solutions. These new leaders are part of ... to support client demand for the company’s big data ... of its partner network. , Since the company ...
(Date:12/22/2014)... Give a loved one the greatest gift of ... vitality. , For a limited time, HealthiPlus ( https://healthiplus.com/christmas-gift-packages/ ... special Holiday Wellness gift packages at drastically reduced prices ... contains cutting-edge, proven nutritional support for joints, mental functioning ... we age. , Joint Health Plus contains ...
(Date:12/22/2014)... December 22, 2014 The MedTech industry is ... a wholly owned subsidiary of PartnerTech AB of Sweden, is ... recently achieved additional ISO Certification. , All signs point to ... and the likelihood of a repeal of the excise tax ... The industry is anticipating annual growth of 9.3% and PartnerTech ...
(Date:12/22/2014)... New York NY (PRWEB) December 22, 2014 ... reports that a federal panel of judges has granted ... lawsuits in the U.S. District Court, Eastern District ... (JPML) issued an order on December 12 to transfer ... actions–pending in 22 districts to the Louisiana court for ...
(Date:12/22/2014)... December 22, 2014 TheHardwareCity.com now stocks ... with many useful features. Customers of the large online ... the new gloves delivered to their home or workplace ... hand tools that incorporate heavy duty magnets, which make ... allows workers to store metal parts on the back ...
Breaking Medicine News(10 mins):Health News:Explorys Continues to Experience Rapid Growth, Adds Three Healthcare IT Executives to Its Leadership Team 2Health News:Explorys Continues to Experience Rapid Growth, Adds Three Healthcare IT Executives to Its Leadership Team 3Health News:You Still Have Time to Give the Gift of Health and Vitality to a Mature Loved One 2Health News:PartnerTech Inc. Poised for Growth in MedTech 2Health News:Panel Orders Xarelto Lawsuits Consolidated Into Multi-District Litigation Reports Alonso Krangle LLP 2Health News:Panel Orders Xarelto Lawsuits Consolidated Into Multi-District Litigation Reports Alonso Krangle LLP 3Health News:Panel Orders Xarelto Lawsuits Consolidated Into Multi-District Litigation Reports Alonso Krangle LLP 4Health News:MagnoGrip Pro Utility Magnetic Gloves on Sale at TheHardwareCity.com 2
... in the international research consortium named MetaHit, scientists from ... an individual,s intestinal bacteria flora, regardless of nationality, gender ... of intestinal bacteria flora is hypothesised to have an ... and medicine absorbed through the gastro-intestinal tract. The results ...
... , WEDNESDAY, April 20 (HealthDay News) -- Poor ... more likely than others to cut back on health ... to a new study. Conducted by the RAND ... earlier studies, which found that so-called "medically vulnerable" people ...
... Queen,s University professor Kate Harkness has found that a ... substantially increases the risk of depression in adolescence by ... Adolescents with a history of maltreatment and a mild ... of the stress hormone cortisol than is normal in ...
... Men are more likely to see issues in black-and-white, whereas women ... contends. British researchers asked 113 volunteers to judge how 50 ... The objects and categories were highly likely to stimulate debate or ... a tool? Men were found to be more likely to ...
... School of Medicine researcher has developed a potential ... prevalent sexually transmitted disease and the leading cause ... Ph.D., professor of immunology and microbiology, internal medicine ... demonstrated a vaccine effect to inoculate against Chlamydia ...
... of severe traumatic brain injury (TBI), the U.S. Department ... this type of injury receive adequate protein and calories ... weeks of treatment, says a new report from the ... severely brain-injured patients shows that providing energy and protein ...
Cached Medicine News:Health News:What's your intestinal bacteria type? 2Health News:High-Deductible Health Plans Bring Equal Savings to All: Study 2Health News:WSU files for patent on researcher's vaccine technology for chlamydia 2Health News:WSU files for patent on researcher's vaccine technology for chlamydia 3Health News:WSU files for patent on researcher's vaccine technology for chlamydia 4Health News:Protein and calories can help lessen effects of severe traumatic brain injury 2
For the direct colorimetric determination of alkaline phosphatase in human serum....
Auto LDL-Cholesterol, automated analyzer test kits....
For the quantitative determination of uric acid in serum....
For the quantitative determination of uric acid in serum....
Medicine Products: